ATC Group: B03XA Other antianemic preparations

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of B03XA in the ATC hierarchy

Level Code Title
1 B Blood and blood forming organs
2 B03 Antianemic preparations
3 B03X Other antianemic preparations
4 B03XA Other antianemic preparations

Group B03XA contents

Code Title
B03XA01 Erythropoietin
B03XA02 Darbepoetin alfa
B03XA03 Methoxy polyethylene glycol-epoetin beta
B03XA04
B03XA05
B03XA06
B03XA07
B03XA08

Active ingredients in B03XA

Active Ingredient Description
Daprodustat

Daprodustat is indicated for the treatment of anemia due to chronic kidney disease. Daprodustat is a reversible inhibitor of HIF-PH1, PH2 and PH3 (IC50 in the low nM range). This activity results in the stabilization and nuclear accumulation of HIF-1α and HIF-2α transcription factors, leading to increased transcription of the HIF-responsive genes, including erythropoietin.

Darbepoetin alfa

Darbepoetin alfa stimulates erythropoiesis by the same mechanism as the endogenous hormone. Darbepoetin alfa has five N-linked carbohydrate chains whereas the endogenous hormone and recombinant human erythropoietins (r-HuEPO) have three. The additional sugar residues are molecularly indistinct from those on the endogenous hormone. Due to its increased carbohydrate content darbepoetin alfa has a longer terminal half-life than r-HuEPO and consequently a greater in vivo activity.

Epoetin alfa

Epoetin alfa is a glycoprotein hormone produced primarily by the kidney in response to hypoxia and is the key regulator of red blood cell (RBC) production. Epoetin alfa is involved in all phases of erythroid development, and has its principal effect at the level of erythroid precursors.

Epoetin beta

Epoetin beta stimulates erythropoiesis by interaction with the erythropoietin receptor on progenitor cells in the bone marrow. Epoetin beta is a continuous erythropoietin receptor activator that shows a different activity at the receptor level characterized by a slower association to and faster dissociation from the receptor, a reduced specific activity in vitro with an increased activity in vivo, as well as an increased half-life, in contrast to erythropoietin.

Epoetin theta

Epoetin theta is identical in its amino acid sequence and similar in its carbohydrate composition (glycosylation) to endogenous human erythropoietin. After administration of epoetin theta, the number of erythrocytes, the haematocrit values and reticulocyte counts increase.

Epoetin zeta

Epoetin zeta is a recombinant human erythropoietin. Erythropoietin (EPO) is a glycoprotein hormone produced primarily by the kidney in response to hypoxia and is the key regulator of red blood cell (RBC) production. The 2 are indistinguishable on the basis of functional assays.

Luspatercept

Luspatercept, an erythroid maturation agent, is a recombinant fusion protein that binds selected transforming growth factor-β (TGF-β) superfamily ligands. By binding to specific endogenous ligands (e.g. GDF-11, activin B) luspatercept inhibits Smad2/3 signalling, resulting in erythroid maturation through differentiation of late-stage erythroid precursors (normoblasts) in the bone marrow.

Roxadustat

Roxadustat is a hypoxia-inducible factor, prolyl hydroxylase inhibitor (HIF-PHI). The activity of HIF-PH enzymes controls intracellular levels of HIF, a transcription factor that regulates the expression of genes involved in erythropoiesis. Activation of the HIF pathway is important in the adaptative response to hypoxia to increase red blood cell production.

Vadadustat

Vadadustat is a hypoxia-inducible factor prolyl-hydroxylase inhibitor which leads to increased cellular levels of hypoxia-inducible factor thereby stimulating endogenous erythropoietin (EPO) production, increasing iron mobilization and red blood cell production, resulting in gradual rate of rise in Hb.

Related product monographs

Title Information Source Document Type  
ABSEAMED Solution for injection in a pre-filled syringe European Medicines Agency (EU) MPI, EU: SmPC
ARANESP Solution for injection in pre-filled syringe / pre-filled pen / vial European Medicines Agency (EU) MPI, EU: SmPC
BINOCRIT Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
BIOPOIN Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
EPOGEN Solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR
EPORATIO Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
EVRENZO Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
JESDUVROQ Film coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
MIRCERA Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
REBLOZYL Powder for solution for injection European Medicines Agency (EU) MPI, EU: SmPC
REBLOZYL Powder for solution for injection / infusion FDA, National Drug Code (US) MPI, US: SPL/PLR
RETACRIT Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
SILAPO Solution for injection in pre-filled syringe European Medicines Agency (EU) MPI, EU: SmPC
VAFSEO Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC